Stacy Lindborg - 06 Sep 2025 Form 4 Insider Report for Imunon, Inc. (IMNN)

Reporting relationship: President and CEO, Director
Issuer ticker: IMNN
Reported as of: 06 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Sep 2025, 16:14:01 UTC
Prior SEC filing: 06 Aug 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg

Key filing fact

Stacy Lindborg filed Form 4 for Imunon, Inc. (IMNN) on 09 Sep 2025.

Key facts

This page summarizes Stacy Lindborg's Form 4 filing for Imunon, Inc. (IMNN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Sep 2025, 16:14.

Change

Previous filing in this sequence was filed on 06 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001813667 Primary reporting owner

Lindborg Stacy

Relationship: President and CEO, Director
Address: C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE
Signature: /s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg
Signature date: 09 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +1,667
Change %: +87%
Price: $0.000000
Shares after: 3,584
Date: 06 Sep 2025
Ownership: Direct
Footnotes: F1

IMNN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 234
Date: 06 Sep 2025
Ownership: By 401(k) Plan

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNN transaction Derivative

Restricted Stock

Options Exercise

Transaction value: $0
Shares: -1,667
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 06 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,667
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024.

Footnote F2

Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock.

Footnote F3

On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date.

SEC remarks

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person. On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.